DURECT Corporation Presenting at the Fifteenth Annual CIBC Healthcare Conference

Download PDF:

CUPERTINO, Calif., Nov 4, 2004 (PRNewswire-FirstCall via COMTEX) — DURECT Corporation announced today that it will present at the Fifteenth Annual CIBC Healthcare Conference. The conference is being held at The Plaza Hotel in New York, New York. Dr. James E. Brown, President and Chief Executive Officer, will be presenting at the conference on Tuesday, November 9th, 2004 at 10:00 a.m. EST.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO )

A live audio webcast of the presentation will be available by accessing DURECT’s homepage at http://www.www.durect.com/ and clicking “Investor Relations.”

About DURECT Corporation

DURECT Corporation is a pharmaceutical company focused on the development of pharmaceutical systems based on its proprietary drug delivery platform technologies that treat chronic debilitating diseases and enable biotechnology products. These platform technologies include the SABER(TM) Delivery System (a patented and versatile depot injectable useful for protein and small molecule delivery), the ORADUR(TM) sustained release oral gel-cap technology (an oral sustained release technology with several potential abuse deterrent properties), the DURIN(TM) Biodegradable Implant (drug-loaded implant system) and the MICRODUR(TM) Biodegradable Microparticulates (microspheres injectable system). DURECT also partners with pharmaceutical companies to develop and commercialize proprietary and enhanced pharmaceutical products based on its technologies. DURECT has five disclosed on-going development programs of which three are in collaboration with pharmaceutical partners. Additional information about DURECT is available at http://www.www.durect.com/.

NOTE: SABER(TM), ORADUR(TM), DURIN(TM) and MICRODUR(TM) are trademarks of DURECT Corporation.

Schond L. Greenway
Executive Director, Investor Relations and Strategic Planning of DURECT Corporation,


Scroll to Top